Join Dr. April Jasper on The Dr. April Jasper Show for an exciting deep dive into the latest breakthrough in presbyopia management! Special guests, renowned eye care experts Dr. Josh Davidson and Dr. Marc Bloomenstein, join the conversation to discuss VIZZ (aceclidine ophthalmic solution) 1.44% — the first and only FDA-approved aceclidine-based prescription eye drop designed to improve age-related blurry near vision in adults.

Discover how this innovative once-daily drop works by creating a pupil-selective “pinhole effect” for enhanced depth of focus, delivering rapid improvement in near vision within 30 minutes and lasting up to 10 hours—with no negative impact to distance vision. Learn about its advantages over previous options, key clinical trial insights from the CLARITY studies, real-world applications for patients, potential side effects, and why VIZZ represents a game-changing, nonsurgical solution for the millions affected by presbyopia.

Whether you’re an eye care professional or someone tired of relying on readers, this episode offers expert perspectives on bringing clearer, more convenient near vision to your patients and practice! Don’t miss this timely discussion on one of the newest tools transforming presbyopia care.

The most common side effects that may be experienced by using VIZZ are eye redness, eye irritation, temporary dim or dark vision and headaches.

Eye care professional? Click the link below.

https://www.vizz.com/ecp?utm_source=podcast&utm_medium=email&utm_campaign=feb2026&utm_id=apriljasper

This podcast is sponsored by and speakers are compensated by LENZ Therapeutics, Inc

.

Did you know there are glasses available to slow the progression of myopia? Listen as Dr Monica Jong shares all about Stellest lenses and myopia control.

In this episode, I’m joined by Dr. Christine Funke, glaucoma surgeon and lead author of the Interventional Glaucoma Consensus Treatment Protocol, for a timely and practice-shaping conversation on the future of glaucoma management.

We explore how interventional approaches are redefining the standard of care—shifting treatment earlier, improving consistency in clinical decision-making, and driving better outcomes for patients. Whether you’re a clinician navigating evolving glaucoma strategies or a patient seeking clarity and confidence in your care, this conversation offers meaningful insight into where glaucoma treatment is headed next.